Abounar et al. and Fierro J. et al. successfully used CRISPR/Cas9 to knock out PD-L1 in lung and glioblastoma cells, respectively, leading to inhibition of tumor growth and invasion, with an enhanced immune response [75,76]. This evidence concerns the gene CD274 and neoplasm.